Bevacizumab as first-line treatment for advanced non-small cell lung cancer

Drugs of Today

Volumn 44, Issue 4, 2008, Pages 293-301

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM;

ABDOMINAL PAIN; ADVANCED CANCER; BLEEDING; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; ELDERLY CARE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MELENA; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 46049094818     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.4.1212302     Document Type: Review

References (25)

1. American Cancer Society. Cancer Facts and Figures 2006.
2. Socinski, M.A., Crowell, R., Hensing, T.E. et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3, Suppl.): 277S-89S.
3. Postmus, P.E., Brambilla, E., Chansky, K. et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007, 2(8): 686-93.
4. Socinski, M.A., Stinchcombe, T.E. Duration of first-line chemotherapy in advanced non small-cell lung cancer: Less is more in the era of effective subsequent therapies. J Clin Oncol 2007, 25(33): 5155-7.
5. Hanahan, D., Weinberg, R. The hallmarks of cancer. Cell 2000, 100(1): 57-70.
6. Stinchcombe, T.E., Socinski, M.A. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007, 26(25): 3691-8.
7. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307(5706): 58-62.
8. Willett, C.G., Boucher, Y., di Tomaso, E. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2): 145-7.
9. Gordon, M.S., Margolin, K., Talpaz, M. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19(3): 843-50.
10. Margolin, K., Gordon, M.S., Holmgren, E. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001, 19(3): 851-6.
11. Johnson, D.H., Fehrenbacher, L., Novotny, W.F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11): 2184-91.
12. Sandler, A., Gray, R., Perry, M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24): 2542-50.
13. Sandler, A.B., Johnson, D.H., Brahmer, J. et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 7068.
14. Manegold, C., Von Pawel, J., Zatloukal, P. et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst LBA7514.
15. Brahmer, J.R., Gray, R., Schiller, J.H., Perry, M., Sandler, A., Johnson, D. ECOG 4599 phase III trial of carboplatin and paclitaxel +/-bevacizumab: Subset analysis of survival by gender. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 7036.
16. Sandler, A.B., Gray, R., Brahmer, J. et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst LBA4.
17. Miller, K., Wang, M., Gralow, J. et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005.
18. Ramalingam, S.S., Dahlberg, S.E., Langer, C.J. et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 7535.
19. Kraut, M.J., Kumar, A., San-Pedro-Salcedo, M., Terebelo, H., Wakelee, H. Safety of gemcitabine and carboplatin plus bevacizumab for advanced stage non-small cell lung cancer (NSCLC): Pooled preliminary safety data from two ongoing studies. J Thorac Oncol [12th World Conf Lung Cancer (Sept 2-6, Seoul) 2007] 2007, 2(8, Suppl. 4): Abst P3-107.
20. William, W.N. Jr., Kies, M.S., Fossella, F.V. et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 18098.
21. Reynolds, C., Barrera, D., Vu, D.Q. et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 7610.
22. Patel, J.D., Hensing, T.A., Villafor, V., Hart, E., Bonomi, P. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 7601.
23. Socinski, M. Personal communication, 2007.
24. Merza, T., Howard, L.M., Junagadhwalla, M., Gajra, A. Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 18046.
25. Herbst, R.S., O'Neill, V.J., Fehrenbacher, L. et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25(30): 4743-50.